AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKTX
  4. [Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

[Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider Trading Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has increased his position through two separate purchases of American Depositary Shares (ADS):

  • June 23, 2025: Acquired 943 ADS at $1.15 per share
  • June 24, 2025: Acquired 5,203 ADS at weighted average price of $1.16

Following these transactions, Gaslightwala now directly owns 277,574 ADS. Each ADS represents 2,000 ordinary shares with $0.0001 par value. The insider's accumulation of shares at these price levels may signal management's confidence in the company's prospects. The Form 4 was filed within the required reporting timeframe and executed by Torsten Hombeck as Attorney-in-Fact.

Avviso di Insider Trading: Abizer Gaslightwala, Presidente, CEO e Direttore di Akari Therapeutics, ha incrementato la sua partecipazione attraverso due acquisti distinti di American Depositary Shares (ADS):

  • 23 giugno 2025: Acquisiti 943 ADS a 1,15 $ per azione
  • 24 giugno 2025: Acquisiti 5.203 ADS a un prezzo medio ponderato di 1,16 $

Dopo queste operazioni, Gaslightwala detiene ora direttamente 277.574 ADS. Ogni ADS rappresenta 2.000 azioni ordinarie con valore nominale di 0,0001 $. L'accumulo di azioni da parte dell'insider a questi livelli di prezzo potrebbe indicare la fiducia del management nelle prospettive della societ脿. Il modulo Form 4 猫 stato presentato entro i termini previsti ed eseguito da Torsten Hombeck in qualit脿 di Procuratore.

Alerta de Operaci贸n con Informaci贸n Privilegiada: Abizer Gaslightwala, Presidente, CEO y Director de Akari Therapeutics, ha aumentado su posici贸n mediante dos compras separadas de American Depositary Shares (ADS):

  • 23 de junio de 2025: adquiri贸 943 ADS a 1,15 $ por acci贸n
  • 24 de junio de 2025: adquiri贸 5,203 ADS a un precio promedio ponderado de 1,16 $

Tras estas transacciones, Gaslightwala posee ahora directamente 277,574 ADS. Cada ADS representa 2,000 acciones ordinarias con un valor nominal de 0,0001 $. La acumulaci贸n de acciones por parte del insider a estos niveles de precio puede indicar la confianza de la direcci贸n en las perspectivas de la empresa. El Formulario 4 fue presentado dentro del plazo requerido y firmado por Torsten Hombeck como Apoderado.

雮措秬鞛� 瓯半灅 鞎岆: Akari Therapeutics鞚� 靷灔 瓴� CEO 氚� 鞚挫偓鞚� Abizer Gaslightwala臧� 霊� 彀鞐� 瓯胳硱 American Depositary Shares (ADS)毳� 於旉皜搿� 毵れ瀰頄堨姷雼堧嫟:

  • 2025雲� 6鞗� 23鞚�: 欤茧嫻 1.15雼煬鞐� 943 ADS 毵れ瀰
  • 2025雲� 6鞗� 24鞚�: 臧�欷戫弶攴� 臧�瓴� 1.16雼煬鞐� 5,203 ADS 毵れ瀰

鞚� 瓯半灅 頉� Gaslightwala電� 順勳灛 歆侅爲 277,574 ADS毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 臧� ADS電� 鞎‰┐臧� 0.0001雼煬鞚� 氤错喌欤� 2,000欤茧ゼ 雮橅儉雰呺媹雼�. 雮措秬鞛愳潣 鞚措煬頃� 臧�瓴╇寑鞐愳劀鞚� 欤检嫕 毵れ瀰鞚� 瓴届榿歆勳澊 須岇偓鞚� 鞝勲鞐� 雽�頃� 鞁犽毳� 臧�歆�瓿� 鞛堨潓鞚� 鞁滌偓頃� 靾� 鞛堨姷雼堧嫟. Form 4電� 攴滌爼霅� 氤搓碃 旮绊暅 雮挫棎 鞝滌稖霅橃棃鞙茧┌, 氩曥爼 雽�毽澑 Torsten Hombeck臧� 鞁ろ枆頄堨姷雼堧嫟.

Alerte sur les Transactions d'Initi茅s : Abizer Gaslightwala, Pr茅sident, CEO et Directeur d'Akari Therapeutics, a augment茅 sa position par deux achats distincts d'American Depositary Shares (ADS) :

  • 23 juin 2025 : Acquisition de 943 ADS au prix de 1,15 $ par action
  • 24 juin 2025 : Acquisition de 5 203 ADS 脿 un prix moyen pond茅r茅 de 1,16 $

Suite 脿 ces transactions, Gaslightwala d茅tient d茅sormais directement 277 574 ADS. Chaque ADS repr茅sente 2 000 actions ordinaires d'une valeur nominale de 0,0001 $. L'accumulation d'actions par l'initi茅 脿 ces niveaux de prix peut indiquer la confiance de la direction dans les perspectives de l'entreprise. Le formulaire 4 a 茅t茅 d茅pos茅 dans les d茅lais requis et sign茅 par Torsten Hombeck en tant que mandataire.

Insider-Handelswarnung: Abizer Gaslightwala, Pr盲sident, CEO und Direktor von Akari Therapeutics, hat seine Position durch zwei getrennte K盲ufe von American Depositary Shares (ADS) erh枚ht:

  • 23. Juni 2025: Erwerb von 943 ADS zu je 1,15 $
  • 24. Juni 2025: Erwerb von 5.203 ADS zum gewichteten Durchschnittspreis von 1,16 $

Nach diesen Transaktionen besitzt Gaslightwala nun direkt 277.574 ADS. Jede ADS repr盲sentiert 2.000 Stammaktien mit einem Nennwert von 0,0001 $. Die Ansammlung von Aktien durch den Insider zu diesen Kursniveaus k枚nnte auf das Vertrauen des Managements in die Aussichten des Unternehmens hinweisen. Das Formular 4 wurde fristgerecht eingereicht und von Torsten Hombeck als Bevollm盲chtigter ausgef眉hrt.

Positive
  • CEO Abizer Gaslightwala demonstrated confidence through open market purchases of 6,146 ADSs worth approximately $7,100 over two days at $1.15-$1.16 per share
Negative
  • None.

Avviso di Insider Trading: Abizer Gaslightwala, Presidente, CEO e Direttore di Akari Therapeutics, ha incrementato la sua partecipazione attraverso due acquisti distinti di American Depositary Shares (ADS):

  • 23 giugno 2025: Acquisiti 943 ADS a 1,15 $ per azione
  • 24 giugno 2025: Acquisiti 5.203 ADS a un prezzo medio ponderato di 1,16 $

Dopo queste operazioni, Gaslightwala detiene ora direttamente 277.574 ADS. Ogni ADS rappresenta 2.000 azioni ordinarie con valore nominale di 0,0001 $. L'accumulo di azioni da parte dell'insider a questi livelli di prezzo potrebbe indicare la fiducia del management nelle prospettive della societ脿. Il modulo Form 4 猫 stato presentato entro i termini previsti ed eseguito da Torsten Hombeck in qualit脿 di Procuratore.

Alerta de Operaci贸n con Informaci贸n Privilegiada: Abizer Gaslightwala, Presidente, CEO y Director de Akari Therapeutics, ha aumentado su posici贸n mediante dos compras separadas de American Depositary Shares (ADS):

  • 23 de junio de 2025: adquiri贸 943 ADS a 1,15 $ por acci贸n
  • 24 de junio de 2025: adquiri贸 5,203 ADS a un precio promedio ponderado de 1,16 $

Tras estas transacciones, Gaslightwala posee ahora directamente 277,574 ADS. Cada ADS representa 2,000 acciones ordinarias con un valor nominal de 0,0001 $. La acumulaci贸n de acciones por parte del insider a estos niveles de precio puede indicar la confianza de la direcci贸n en las perspectivas de la empresa. El Formulario 4 fue presentado dentro del plazo requerido y firmado por Torsten Hombeck como Apoderado.

雮措秬鞛� 瓯半灅 鞎岆: Akari Therapeutics鞚� 靷灔 瓴� CEO 氚� 鞚挫偓鞚� Abizer Gaslightwala臧� 霊� 彀鞐� 瓯胳硱 American Depositary Shares (ADS)毳� 於旉皜搿� 毵れ瀰頄堨姷雼堧嫟:

  • 2025雲� 6鞗� 23鞚�: 欤茧嫻 1.15雼煬鞐� 943 ADS 毵れ瀰
  • 2025雲� 6鞗� 24鞚�: 臧�欷戫弶攴� 臧�瓴� 1.16雼煬鞐� 5,203 ADS 毵れ瀰

鞚� 瓯半灅 頉� Gaslightwala電� 順勳灛 歆侅爲 277,574 ADS毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 臧� ADS電� 鞎‰┐臧� 0.0001雼煬鞚� 氤错喌欤� 2,000欤茧ゼ 雮橅儉雰呺媹雼�. 雮措秬鞛愳潣 鞚措煬頃� 臧�瓴╇寑鞐愳劀鞚� 欤检嫕 毵れ瀰鞚� 瓴届榿歆勳澊 須岇偓鞚� 鞝勲鞐� 雽�頃� 鞁犽毳� 臧�歆�瓿� 鞛堨潓鞚� 鞁滌偓頃� 靾� 鞛堨姷雼堧嫟. Form 4電� 攴滌爼霅� 氤搓碃 旮绊暅 雮挫棎 鞝滌稖霅橃棃鞙茧┌, 氩曥爼 雽�毽澑 Torsten Hombeck臧� 鞁ろ枆頄堨姷雼堧嫟.

Alerte sur les Transactions d'Initi茅s : Abizer Gaslightwala, Pr茅sident, CEO et Directeur d'Akari Therapeutics, a augment茅 sa position par deux achats distincts d'American Depositary Shares (ADS) :

  • 23 juin 2025 : Acquisition de 943 ADS au prix de 1,15 $ par action
  • 24 juin 2025 : Acquisition de 5 203 ADS 脿 un prix moyen pond茅r茅 de 1,16 $

Suite 脿 ces transactions, Gaslightwala d茅tient d茅sormais directement 277 574 ADS. Chaque ADS repr茅sente 2 000 actions ordinaires d'une valeur nominale de 0,0001 $. L'accumulation d'actions par l'initi茅 脿 ces niveaux de prix peut indiquer la confiance de la direction dans les perspectives de l'entreprise. Le formulaire 4 a 茅t茅 d茅pos茅 dans les d茅lais requis et sign茅 par Torsten Hombeck en tant que mandataire.

Insider-Handelswarnung: Abizer Gaslightwala, Pr盲sident, CEO und Direktor von Akari Therapeutics, hat seine Position durch zwei getrennte K盲ufe von American Depositary Shares (ADS) erh枚ht:

  • 23. Juni 2025: Erwerb von 943 ADS zu je 1,15 $
  • 24. Juni 2025: Erwerb von 5.203 ADS zum gewichteten Durchschnittspreis von 1,16 $

Nach diesen Transaktionen besitzt Gaslightwala nun direkt 277.574 ADS. Jede ADS repr盲sentiert 2.000 Stammaktien mit einem Nennwert von 0,0001 $. Die Ansammlung von Aktien durch den Insider zu diesen Kursniveaus k枚nnte auf das Vertrauen des Managements in die Aussichten des Unternehmens hinweisen. Das Formular 4 wurde fristgerecht eingereicht und von Torsten Hombeck als Bevollm盲chtigter ausgef眉hrt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gaslightwala Abizer
(Last) (First) (Middle)
C/O AKARI THERAPEUTICS PLC
22 BOSTON WHARF ROAD FL 7
(Street)
BOSTON MA 02210
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares representing Ordinary Shares(1) 06/23/2025 P 943 A $1.15 272,371 D
American Depositary Shares representing Ordinary Shares(1) 06/24/2025 P 5,203 A $1.16(2) 277,574 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote.
/s/ Torsten Hombeck, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many AKTX shares did CEO Abizer Gaslightwala purchase in June 2025?

CEO Abizer Gaslightwala purchased a total of 6,146 American Depositary Shares (ADS) over two days: 943 shares at $1.15 per share on June 23, 2025, and 5,203 shares at an average price of $1.16 on June 24, 2025.

What is AKTX CEO's total share ownership after the June 2025 purchases?

Following the reported transactions, CEO Abizer Gaslightwala directly owns 277,574 American Depositary Shares of Akari Therapeutics (AKTX). Each ADS represents 2,000 Ordinary Shares of the company.

What was the purchase price range for AKTX shares in the CEO's June 24, 2025 transaction?

On June 24, 2025, the CEO purchased shares at prices ranging from $1.15 to $1.16 per share, with a weighted average price of $1.16. The exact number of shares purchased at each price point within this range was not disclosed in the filing.

What positions does Abizer Gaslightwala hold at AKTX according to the Form 4?

According to the Form 4 filing, Abizer Gaslightwala serves as both a Director and President & CEO of Akari Therapeutics Plc (AKTX).
Stock AKTX logo
Akari Therapeutics Plc

NASDAQ:AKTX

AKTX Rankings

#5441 Ranked by Market Cap
N/A Ranked by Dividends

AKTX Latest News

Aug 14, 2025
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Jul 29, 2025
Akari Therapeutics Releases Virtual Investor 鈥淲hat This Means鈥� Segment
Jul 23, 2025
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
Jul 22, 2025
Akari Therapeutics Participates in the Virtual Investor 鈥淲hat鈥檚 Your Story鈥� Summer Spotlight On-Demand Conference
Jun 25, 2025
Akari Therapeutics Releases Virtual Investor 鈥淲hat This Means鈥� Segment Highlighting its Recently Granted India Patent

AKTX Latest SEC Filings

Aug 13, 2025
[10-Q] Akari Therapeutics plc ADR (0.01 USD) Quarterly Earnings Report
Jul 29, 2025
[S-8] Akari Therapeutics plc ADR (0.01 USD) Employee Benefit Plan Registration
Jul 29, 2025
[S-3] Akari Therapeutics plc ADR (0.01 USD) Shelf Registration Statement
Jul 1, 2025
[8-K] Akari Therapeutics plc ADR (0.01 USD) Reports Material Event
Jun 24, 2025
[Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

AKTX Stock Data

33.79M
21.01M
34.7%
0.91%
0.11%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON